Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ya Chen

Showing results (761-770 of 1,603) with videos related to

Pageof 161
Sort By:
Frontiers in Pharmacology|August 29, 2022
Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling PathwayGuoxiang Tong, Tianhao Peng, Ya Chen, et al.
Optics Express|February 25, 2022
Denoising in SVD-based ghost imagingLiu-Ya Chen, Chong Wang, Xu-Yi Xiao, et al.
Hu Li Za Zhi the Journal of Nursing|January 26, 2022
[Evaluation of the Nurses' Utilization of the Pain Management Information System Based on the Information System Success Model]Li-Ya Chen, Yu-Ching Sun, Ching-Ru Cheng, et al.
Pharmacoeconomics|July 10, 2019
Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare DataYa-Chen Tina Shih, Ying Xu, Chun-Ru Chien, et al.
Frontiers in Immunology|March 3, 2022
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung CancerZhengyu Yang, Ya Chen, Yanan Wang, et al.
Metabolites|February 25, 2023
Exposure to Heavy Metals and Serum Adiponectin Levels among Workers: A 2-Year Follow-Up StudyChen-Jung Wu, A-Chuan Ho, Shih-Ya Chen, et al.
Bioorganic & Medicinal Chemistry|November 8, 2022
Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromaroneWanqiu Huang, Shixuan Jiao, Siliang Chen, et al.
Frontiers in Oncology|May 3, 2021
Pembrolizumab Plus Chemotherapy or Anlotinib <i>vs.</i> Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLCYa Chen, Zhengyu Yang, Yanan Wang, et al.
Journal of Aging and Physical Activity|May 30, 2020
Training Program With Outdoor Fitness Equipment in Parks Offers No Substantial Benefits for Functional Fitness in Active Seniors: A Randomized Controlled TrialYa-Chen Liu, Wen-Wen Yang, I-Yao Fang, et al.
The European Journal of Neuroscience|March 6, 2023
Myelination dictates axonal viscoelasticityYa-Chen Chuang, Ace Alcantara, Gloria Fabris, et al.
Pageof 161

Showing results (761-770 of 1,603) with videos related to

Sort By:
Pageof 161
Frontiers in Pharmacology|August 29, 2022
Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling PathwayGuoxiang Tong, Tianhao Peng, Ya Chen, et al.
Optics Express|February 25, 2022
Denoising in SVD-based ghost imagingLiu-Ya Chen, Chong Wang, Xu-Yi Xiao, et al.
Hu Li Za Zhi the Journal of Nursing|January 26, 2022
[Evaluation of the Nurses' Utilization of the Pain Management Information System Based on the Information System Success Model]Li-Ya Chen, Yu-Ching Sun, Ching-Ru Cheng, et al.
Pharmacoeconomics|July 10, 2019
Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II-An Updated Analysis of SEER-Medicare DataYa-Chen Tina Shih, Ying Xu, Chun-Ru Chien, et al.
Frontiers in Immunology|March 3, 2022
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung CancerZhengyu Yang, Ya Chen, Yanan Wang, et al.
Metabolites|February 25, 2023
Exposure to Heavy Metals and Serum Adiponectin Levels among Workers: A 2-Year Follow-Up StudyChen-Jung Wu, A-Chuan Ho, Shih-Ya Chen, et al.
Bioorganic & Medicinal Chemistry|November 8, 2022
Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromaroneWanqiu Huang, Shixuan Jiao, Siliang Chen, et al.
Frontiers in Oncology|May 3, 2021
Pembrolizumab Plus Chemotherapy or Anlotinib <i>vs.</i> Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLCYa Chen, Zhengyu Yang, Yanan Wang, et al.
Journal of Aging and Physical Activity|May 30, 2020
Training Program With Outdoor Fitness Equipment in Parks Offers No Substantial Benefits for Functional Fitness in Active Seniors: A Randomized Controlled TrialYa-Chen Liu, Wen-Wen Yang, I-Yao Fang, et al.
The European Journal of Neuroscience|March 6, 2023
Myelination dictates axonal viscoelasticityYa-Chen Chuang, Ace Alcantara, Gloria Fabris, et al.
Pageof 161